{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Investigational
Source:
INN:teserpaturev [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:lasmecabtagene timgedleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
USAN:GEMOGENOVATUCEL-T [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:marnetegragene autotemcel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04093596: Phase 1 Interventional Active, not recruiting Relapsed/Refractory Multiple Myeloma
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03294083: Phase 1/Phase 2 Interventional Active, not recruiting Renal Cell Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
USAN:TONOGENCHONCEL-L [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2013)
First approved in 2013
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2007
Class:
PROTEIN
Status:
Investigational
Source:
NCT01227564: Phase 2 Interventional Completed Alzheimer's Disease
(2011)
Source URL:
Class:
PROTEIN
